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Objectives: Heterogeneity can distort traditional indirect comparisons of treat-
ments. Simulated treatment comparisons (STC) can overcome this with regres-
sion equations to balance differences in populations. Equations are derived using 
patient-level data from one trial (drug A, index); however, only mean values of 
predictors are typically known for the comparator (B). Thus, adjusted results must 
be generated by plugging these means in the equation, which can be biased for 
non-linear outcomes (e.g., time-to-event) since it yields the geometric rather than 
the required arithmetic mean. We describe a solution and illustrate its application 
in an STC of treatments of non-valvular atrial fibrillation (NVAF). MethOds: Data 
from the trial of drug A were used to derive an equation for the rate of major bleeds 
(MB) using Poisson regression. Predictors included gender, age, region, history of 
stroke/transient ischemic attack, hypertension, diabetes, renal dysfunction, prior 
use of various treatments. To avoid non-linearity bias, patient profiles were simu-
lated by sampling predictor values from a multivariate-normal distribution with 
means set to drug B’s population and covariance matrix derived from the index 
trial. The average predicted rate for simulated patients represents the adjusted 
MB rate. To demonstrate that the approach works, we also apply it to the index 
trial. Results: A rate of 21 MBs/1000 person-years were observed with drug A. The 
predicted rate at the means of predictors of patients on drug A produced an estimate 
of 19 (16.4-21.0), whereas the mean of predicted rates with actual profiles was 22 
(15.1-31.9). Repeating the calculations with simulated patients yielded 22.5 (15.3-
33.0). The simulated MB rate in patients matching of the population of drug B was 
30 (20.5-45.1), which contrasted with its observed rate (36.0) yielded a rate ratio of 
0.84 (0.56-1.27). cOnclusiOns: Predicting outcomes with a simulated comparator 
population produces accurate adjusted results for use in STCs.
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Objectives: To evaluate new medicines, Health Technology Assessment (HTA) 
agencies must have comparative data. With the lack of randomized trials versus all 
comparators, pharmaceutical companies have increasingly used indirect compari-
sons. The objective of the present study was to describe the impact of the method-
ology of the indirect comparison both on the ASMR determination and efficiency 
opinions given by the French National Authority for Health (HAS). MethOds: Two 
retrospective studies were conducted in order to select HTA opinions mention-
ing indirect comparisons (using the keywords “indirect” or “network”) using inter-
nal databases of HAS. The first study was related on HTA opinions given by the 
Transparency Committee (TC) from July 2009 to October 2014. The second study 
analyzed efficiency opinions issued by the Commission of Economic Evaluation 
and Public Health (CEESP) from October 2013 to December 2014. For each study, 
we recorded: the method of indirect comparison used, the acceptability, the criti-
cisms and the impact on decision-making. Results: We identified 61 indirect com-
parisons from HTA opinions given by the TC. Among these, the TC considered 30 
methodologically unacceptable. Network meta-analysis, the method recommended 
by the HAS, was used in 46% of cases. Only 6/61 indirect comparisons were valid, 
allowing to prioritize the treatment, and were consistent with the « improvement 
of the medical service provided » (ASMR) assigned. In the second study out of 14 
opinions of efficiency given by the CEESP, 4 included indirect comparisons (29%) and 
they were all considered as acceptable. cOnclusiOns: For the TC, the results of 
indirect comparisons are considered as complementary evidence, and are not deci-
sive elements for the ASMR opinion. Conversely, CEESP accepted more frequently 
results of indirect comparisons into economic evaluations. This apparent difference 
in considering and using indirect comparisons by these two commissions of the 
HAS may be explained by their different objectives.
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Objectives: To propose a sample size calculation method for randomized trial-
based cost-effectiveness analyses (RTBCEA), coherent with recommendations to 
express uncertainty through cost-effectiveness probabilities and expected value of 
information. MethOds: Let’s estimate the sample size of a RTBCEA with 2 parallel-
groups of equal size n, assuming equal variance of costs (s²C) and effectiveness 
(s²E) in each group. Our method is based on the incremental net monetary benefit 
(b~N(μ b,σ ²b)). A realization of this random variable in the planned RTBCEA would 
yield a sampling distribution of mean μ b and variance 2σ ²bi/n, where σ ²biis the vari-
ance of the individual net monetary benefit in each group. σ ²bi= λ ²σ ²E+σ ²C–2λ ρ σ Eσ C, 
where λ is the ceiling cost-effectiveness ratio, and ρ the correlation between cost and 
effectiveness. Using this sampling distribution of b, the remaining value of perfect 
information (or the expected value of perfect information depending on n (EVPI(n))) 
is calculated, specifying the size of the target population (N) and a discount rate 
(r). The total cost of the planned RTBCEA is defined by a fixed cost (Cf) and a cost/
patient (Cv). The optimal sample size of one arm in the planned RTBCEA is n when 
EVPI(n)= Cf+2nCv. An application compares sample sizes calculated through our 
method and through a method using statistical inference. Results: Application’s 
data are: σ C= 2100€ , σ E= 2100QALY, ρ = 0.1, λ = 20000€ /QALY, N= 52000/year, r= 0.04, 
time horizon for the calculation of EVPI= 20 years, difference in mean costs= -168€ , 
and difference in mean QALY= 0.04. σ ²bi= 9162002.53 Cf= 81531€ , and Cv= 2257.25€ 
The optimal sample size estimated through our method was 123 patients/group, 
compared to 153/group using the method based on a statistical test with a 80% 
power and a 5% alpha risk. cOnclusiOns: Our method is perfectly coherent with 
recommendations for analyzing cost-effectiveness data and sets the optimal sample 
NICE, IQWiG, CADTH, HAS and EUnetHTA) were reviewed to identify recommen-
dations made forBayesian NMAs in the context of HTAs. Examples of HTA sub-
missions from manufacturers were used to identify how Bayesian results are 
reported in practiceIn order to ensure clarity and simplicity, a guide to interpret 
these results was developed in collaboration with analysts not trained in Bayesian 
statistics. This guide is illustrated with an example of NMA. Results: Bayesian 
analyses are often used in the conduct of NMAs meant to inform cost-effectiveness 
models. Results are generally reported as median or mean of the posterior distribu-
tion, standard deviation, 95% credible intervals and forest plots. Additional results 
include the probability for each treatment of ranking first, the SUCRA (Surface 
Under the Cumulative Ranking) and the probability for the intervention to perform 
better than its comparators. Although it could help interpret the findings, graphi-
cal representation of the posterior distribution is not commonly reported in HTA. 
Sensitivity analyses are also often reported, mainly to assess the robustness of 
the results. cOnclusiOns: Our guide is useful to analysts not trained in Bayesian 
statistics for decision-making purposes in the context of HTA submissions. More 
specifically, it is a straightforward reference tool for using NMA results to populate 
cost-effectiveness models.
PRM206
non-adheRence and non-PeRsIsTence shoUld be analyzed sePaRaTely: 
The exaMPle of MeThoTRexaTe (MTx) TheRaPy In The TheRaPy of newly 
TReaTed RheUMaToId aRThRITIs In geRMany
Mueller S1, Krueger K2, Flacke J3, Heinrich H3, Fuchs A4, Maywald U5, Wilke T6
1IPAM, Wismar, Germany, 2Praxiszentrum St. Bonifatius, München, Germany, 3Roche Pharma 
AG, Grenzach, Germany, 4AOK PLUS, Dresden, Germany, 5AOK Plus, Dresden, Germany, 6Ingress 
Health, Wismar, Germany
Objectives: In most adherence studies, results are shown as overall medication 
possession ratio (MPR). The aim of this study was to show how non-adherence 
(NA) rates of German patients with rheumatoide arthritis (RA) having initiated a 
methotrexate (MTX) therapy change if adherence is analyzed as overall MPR includ-
ing periods of therapy discontinuation (NP) or, alternatively, for periods of treat-
ment continuation only. MethOds: Claims data from a German sickness fund 
(AOK PLUS) covering the years 2010-2013 were used. Minimum observational period 
from first MTX-prescription onwards was defined to be 24 months. A medication gap 
of more than 12 weeks was considered to be NP. Adherence was calculated during 
a 12 or 24 month follow-up in two scenarios (for whole period versus for periods 
of therapy continuation between first and last prescription only). NA was defined 
as MPR< 80%. Results: 1,157 MTX-naïve patients (no MTX-prescription in 2010) 
were identified (mean age 61.6 years, 71.8% female, average Charlson Comorbidity 
Index without age factor 2.0). Overall MPR from first prescription until end of the 
12- or 24-months-obserational period for all these patients was 69.7 or 59.9%. Based 
on this, percentage of NA patients was 41.2 or 53.3%. However, 21.2% of patients 
discontinued MTX therapy (NP) within the first 24 months; mean time to discon-
tinuation was 29.1 weeks. If adherence was assessed for periods of therapy con-
tinuation only, the resulting MPR was 95.0% with only 6.4% of patients affected by 
NA. cOnclusiOns: NA and NP describe different real-world phenomena in the 
drug-based treatment of patients and may also be explained by different causes. So, 
NP and NA should be assessed separately. Our analysis shows that the percentage 
of patients poorly implementing therapy is over-estimated if NA is not calculated 
for periods of therapy continuation only.
PRM207
UsIng TangenT lIne segMenTs To deTeRMIne sTaTIsTIcal dIffeRences 
beTween sURvIval cURves aT a sIngle PoInT In TIMe
Wasser T1, Kern DM2, Eisenberg D1
1HealthCore Inc., Wilmington, DE, USA, 2HealthCore Inc, Wilmington, DE, USA
Objectives: Typical survival analysis examines differences in curves across the 
entire spectrum of time. Often the research question relates to differences in sur-
vival at a single point in time without considering other aspects of the survival 
curve. MethOds: This research used data from the United States Surveillance, 
Epidemiology and End Results Program (US-SEER), comparing cervical and ovar-
ian cancer 5-year survival rates from 2007-2011. The steps in this analysis are: 1. 
Calculate Kaplan-Meier curve (or any survival curve) using standard methods, 2. 
Calculate the quadratic curve for the survival measure and record the formula. 
3. Using the point of interest (in this example 12 months) calculate the tangent 
line for that point, using the derivative power method. These two slope values are 
tested against each other using standard slope comparisons. 4. Use the standard 
error of the model for the quadratic equation for significance testing. 5. Test the 
difference between slopes for significance using standard statistical methods for 
slope comparisons. Results: Quadratic formulas were determined for both ovarian 
and cervical cancer survival curves and the tangent lines were calculated using the 
derivative for the equation from the curve. This resulted in two slope values at 12 
months (cervical 4.116 and ovarian 7.151). Using the standard errors for the cervix 
and ovarian groups (2.268 and 3.854 respectively), the Z-value= 0.6787 and p= 0.497, 
indicating the trajectory of survival for cervical and ovarian cancer are not statisti-
cally different from each other even though the point estimates of survival (88.4% 
for cervical; 75.4% for ovarian) are statistically different from each other at that 
point. cOnclusiOns: The strengths of this method is that a single point difference 
test can be conducted for a single point in time based on the trajectory of the line. 
This method does not pool the data across all points. Several other examples will 
be presented graphically.
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